多重原发性肺癌与驱动基因突变:有针对性的治疗是否总是最佳选择?-一个病例报告
Zi-Rui Ren1, Lv Wu1, Chang Lu1
1Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Thoracic cancer
|January 6, 2026
概括
针对性治疗在多重原发性肺癌 (MPLC) 中是有限的,原因是分子差异. 化疗免疫疗法有效治疗异质的MPLC病变,使手术成为可能,但早期复发突出了未满足的需求.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
- 分子病理学分子病理学
背景情况:
- 司机突变肺癌通常会对向治疗做出反应.
- 多重原发性肺癌 (MPLCs) 由于病变间的分子异质性而存在挑战.
- 针对MPLC的向治疗的疗效受到病变中多样化的分子配置文件的限制.
研究的目的:
- 展示一个具有显著分子异质性的同步MPLC的案例.
- 在MPLC中评估针对性治疗和随后的化疗免疫治疗的反应.
- 讨论MPLC治疗策略的影响.
主要方法:
- 一位患有同步MPLC和34个肺结节的患者的病例报告.
- 用EGFR向疗法 (osimertinib) 治疗,然后进行化疗免疫疗法.
- 切除病变的分子分析和治疗反应和复发模式的分析.
主要成果:
- 主导性EGFR突变的病变对奥西默蒂尼布有反应,但其他结节进展.
- 化疗免疫疗法诱导了所有病变的回归,允许手术切除.
- 在切除的病变中发现了不一致的分子概况 (EGFR突变与驱动负).
- 尽管有辅助疗法,但仍有驱动负面特征的早期复发发生,导致迅速下降.
结论:
- 单剂向疗法由于分子异质性而对MPLC存在局限性.
- 驱动器阴性MPLC病变可能不遵循惰的过程.
- 建议MPLC早期的联合策略包括化疗,以解决异质性问题.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer
53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K


